First evaluation of fibroblast growth factor 21 levels in patients diagnosed with glycogen storage diseases with liver involvement
This is the first study to evaluate FGF21 levels in patients with GSD. FGF21 levels in this cohort were comparable to those observed in patients with acute fatty liver disease and hepatosteatosis. Although no statistically significant differences were observed across most GSD subtypes, patients with GSD type IXc exhibited notably higher FGF21 levels, indicating that FGF21 may serve as a biomarker for identifying more severe phenotypes of GSD.
Authors
- Deniz Kör (ORCID: https://orcid.org/0000-0001-7659-0500)
- Burcu Köşeci (ORCID: https://orcid.org/0000-0002-0813-6776)
- Esra Kara (ORCID: https://orcid.org/0000-0001-9119-0791)
- A BOZKURT
- Neslihan Önenli Mungan (ORCID: https://orcid.org/0000-0001-7862-3038)
- Ezgi Burgaç (ORCID: https://orcid.org/0000-0003-2936-058X)
- Fatma Derya Bulut (ORCID: https://orcid.org/0000-0003-0529-2404)
- Gülşah Şeydaoğlu (ORCID: https://orcid.org/0000-0002-0899-894X)
- Gülçin Dağlıoğlu (ORCID: https://orcid.org/0000-0003-2454-3723)
- İrem Kaplan
- Nazmiye Tüzel Gündüz (ORCID: https://orcid.org/0009-0002-4836-974X)
Institutions
- Gaziantep Children's Hospital (TR)
- Medical Park Gaziantep Hospital (TR)
- Malatya Devlet Hastanesi (TR)
- Cukurova University (TR)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1515/jpem-2025-0255
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00